In Response: We appreciate the comments from Dr. Toyooka and his colleagues with regard to our article entitled “Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors” ([1][1]). In